R. Natale

Michael Thomas, S. Thongprasert, P. Sunpaweravong, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lymphoscintigraphy in melanoma: initial evaluation of a low protein dose monoclonal antibody cocktail.

R. Wahl, B. Shulkin, R. Natale, 1990, Cancer research.

Phase II trial of sequentially administered cisplatin, cyclophosphamide and doxorubicin for urothelial tract tumors.

W. Whitmore, M. Lesser, R. Natale, 1983, The Journal of urology.

A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study.

A. Wozniak, E. Crawford, B. Blumenstein, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A critical analysis of response criteria in patients with prostatic cancer treated with CIS‐diamminedichloride platinum II

W. Whitmore, H. Grabstald, R. Natale, 1979, Cancer.

Phase 1 Drug Interaction Study of Suramin and Warfarin in Patients With Prostate Cancer

W. Slichenmyer, M. Meyer, M. Meyer, 2001, American journal of clinical oncology.

A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.

R. Natale, A. Forastiere, M. P. Goren, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

0i Integrin Expression on Human Small Cell Lung Cancer Cells1

R. Natale, R. Todd, L. Feldman, 2006 .

A novel bombesin receptor antagonist inhibits autocrine signals in a small cell lung carcinoma cell line.

E. Sausville, R. Jensen, J. Mulshine, 1988, Biochemical and biophysical research communications.

Combined pneumocystis carinii and nocardia asteroides pneumonitis in a patient with an ACTH‐producing carcinoid

D. Stover, R. Natale, A. Yagoda, 1981, Cancer.

ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial.

R. Govindan, M. Ranson, N. Rizvi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer.

R. Natale, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

J. Ahn, M. Ahn, Dong-Wan Kim, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Progress in small-cell lung cancer: the lowest common denominator.

D. Gandara, P. Lara, R. Natale, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association between anaplastic lymphoma kinase rearrangements (rALK) and the clinical activity of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with non-small cell lung cancer (NSCLC).

L. Sequist, N. Senzer, S. Gettinger, 2010 .

Adjuvant and neoadjuvant chemotherapy for invasive bladder cancer

R. Natale, 2000, Current oncology reports.

Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study.

M. Ahn, Dong-Wan Kim, J. Yang, 2017 .

Phase (ph) 2 study of bortezomib ± docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC): Preliminary results

K. Kelly, F. Fossella, J. Schiller, 2004 .

O-103 A comparison of the antitumour efficacy of ZD6474 and gefitinib(Iressa™) in patients with NSCLC: Results of a randomized, double-blind Phase II study

R. Govindan, M. Ranson, N. Rizvi, 2005 .

O-187 Efficacy and safety of single agent pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in Non-Small Cell Lung Cancer (NSCLC) patients after prior chemotherapy

T. Dang, R. Herbst, V. Miller, 2005 .

Methotrexate: An active drug in bladder cancer

W. Whitmore, R. Natale, A. Yagoda, 1981, Cancer.

Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors

R. Natale, A. Yagoda, M. Blumenreich, 1982, Cancer.

Combined carboplatin and cisplatin. Limited Prospects for Dose Intensification

R. Reynolds, D. Waterhouse, R. Natale, 1993, Cancer.

Surgical factors influence bladder cancer outcomes: a cooperative group report.

H. Grossman, R. deVere White, E. Crawford, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study.

S. Martino, N. Robert, J. Ingle, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Monoclonal antibody (5G6.4) against ovarian carcinoma shows inhibition of in vitro colony formation.

R. Wahl, L. Rodriguez-Rodriguez, R. Natale, 1987, Gynecologic oncology.

Three Primary Tumors Including EGFR-mutated Non-Small Cell Lung Cancer as First Presentation in Patient With Li-Fraumeni Syndrome.

Jae Hyun Kim, R. Natale, E. Vail, 2020, Clinical lung cancer.

A multicenter phase II trial of losoxantrone (DuP-941) in hormone-refractory metastatic prostate cancer.

R. Natale, D. Stewart, P. Stella, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer.

R. Dziadziuszko, G. Weiss, J. Infante, 2015 .

Phase II trial of methyl-GAG in advanced renal cancer.

R. Natale, A. Yagoda, J. Zeffren, 1981, Cancer treatment reports.

A phase I-II trial of cisplatin and dichloromethotrexate in squamous cell cancer of the head and neck.

S. Baker, R. Wheeler, R. Natale, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of methylglyoxal bis-guanylhydrazone (MGBG) in refractory small cell lung cancer

M. Simon, R. Natale, J. Eckenrode, 2004, Investigational New Drugs.

Pharmacokinetic study of aldoxorubicin in patients with solid tumors

M. Mita, A. Mita, S. Wieland, 2014, Investigational New Drugs.

Treatment of patients with small-cell lung cancer at the Memorial Sloan-Kettering Cancer Center, 1974–1979

R. Wittes, B. Hilaris, R. Natale, 1981, World Journal of Surgery.

Phase (Ph) 1/2 study of TSR-011, a potent inhibitor of ALK and TRK, including crizotinib-resistant ALK mutations.

G. Weiss, J. Infante, R. Martell, 2014 .

Gemcitabine and taxane combinations in non small-cell lung cancer.

R. Natale, 2000, Clinical lung cancer.

Combination cisplatin and dichloromethotrexate in patients with advanced or recurrent cervical cancer: a preliminary report.

J. Roberts, R. Wheeler, R. Natale, 1984, Gynecologic oncology.

Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC.

M. Socinski, A. Sandler, L. Miller, 2000, Oncology.

Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lecture.

J. Crowley, M. Leblanc, I. Thompson, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology

E. Messing, I. Thompson, C. Tangen, 2011 .

Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer

R. Herbst, A. Ryan, H. Mann, 2009, Clinical Cancer Research.

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Nicholas J Vogelzang, C. Tangen, H. Grossman, 2003, The New England journal of medicine.

A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A southwest oncology group study

G. Weiss, S. Balcerzak, R. Natale, 1995, Cancer.

An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.

J. Crowley, B. Barlogie, G. Weiss, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of PALA in hypernephroma and urinary bladder cancer.

R. Gralla, D. Kelsen, R. Natale, 1982, Cancer treatment reports.

Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer

A. D. Van den Abbeele, T. Dang, R. Herbst, 2007, Clinical Cancer Research.

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

David Cella, Karen Kelly, Roy S Herbst, 2003, JAMA.

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.

B. Karlan, M. Sliwkowski, D. Agus, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer.

Edward S. Kim, C. Obasaju, M. Socinski, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment

Edward S. Kim, C. Obasaju, M. Socinski, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

Edward S. Kim, N. Reinmuth, M. Ahn, 2020, JAMA oncology.

Molecular and Immune Biomarker Testing in Squamous‐Cell Lung Cancer: Effect of Current and Future Therapies and Technologies

Edward S. Kim, C. Obasaju, M. Socinski, 2018, Clinical lung cancer.

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer

Edward S. Kim, C. Obasaju, M. Socinski, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinicopathologic Features of Advanced Squamous NSCLC.

Edward S. Kim, C. Obasaju, M. Socinski, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

J. Crowley, J. Jett, D. Gandara, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epithelial membrane protein-1 is a biomarker of gefitinib resistance.

S. Shak, D. Agus, Anjali Jain, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

Roy S Herbst, Vincent Miller, Rafael Rosell, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

G. Giaccone, G. Scagliotti, R. Herbst, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.

R. Govindan, M. Ranson, N. Rizvi, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer 1

N. Saijo, D. Gandara, K. Chansky, 2010 .

Tumor hyaluronan as a novel biomarker in non-small cell lung cancer: A retrospective study

R. Patel, J. Gong, R. Tuli, 2022, Oncotarget.

Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer.

H. Keer, T. Reid, R. Natale, 2004, Lung cancer.

Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone.

F. Meyers, E. Small, W. Slichenmyer, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers.

G. Giaccone, M. Socinski, M. Ahn, 2017, Lung cancer.

Irinotecan (CPT-11) in triplet combinations in patients with advanced non small-cell lung cancer: a review and report of a phase I/II trial.

M. Socinski, V. Israel, A. Sandler, 2001, Clinical lung cancer.

Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.

M. Socinski, V. Israel, A. Sandler, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer.

M. Socinski, K. Rowland, R. Lilenbaum, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study.

J. Crowley, C. Coltman, R. Livingston, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).

N. Reinmuth, M. Ahn, F. Shepherd, 2021, Clinical lung cancer.

The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.

C. Langer, R. Natale, 2005, Seminars in oncology.

Pulmonary squamous cell carcinoma and sorafenib

R. Natale, R. Gollard, D. García, 2014, Clinical case reports.

Emerging therapeutic options for advanced non-small cell lung cancer

R. Natale, 2011 .

Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer.

J. Hainsworth, J. Hamm, K. Albain, 2011, Lung cancer.

24 – Adjuvant and Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer

R. Natale, 2010 .

Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC

N. Reinmuth, M. Ahn, S. Peters, 2018, Annals of Oncology.

Do mixed histological features affect survival benefit from neoadjuvant platinum‐based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group‐Directed Intergroup Study (S8710)

E. Messing, I. Thompson, C. Tangen, 2010, BJU international.

Cisplatin and mitoguazone: An induction chemotherapy regimen in advanced head and neck cancer

G. Wolf, R. Wheeler, R. Natale, 1988, Cancer.

Phase II trial of methylglyoxal bis (guanylhydrazone) (MGBG) in advanced head and neck cancer

R. R. Wheeler, R. Natale, Arlene A. Forastiere, 1986, Cancer.

Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma

M. Socinski, V. Israel, A. Sandler, 2002, Cancer.

Methylglyoxal bis-guanylhydrazone in advanced bladder cancer.

D. V. Von Hoff, E. Crawford, M. Eisenberger, 1990, European Journal of Cancer.

An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.

C. Obasaju, R. Ramlau, Joo‐Hang Kim, 2017, Clinical lung cancer.

Healthcare Costs and Workloss Burden of Patients with Chemotherapy-Associated Peripheral Neuropathy in Breast, Ovarian, Head and Neck, and Nonsmall Cell Lung Cancer

H. Birnbaum, R. Natale, C. Pike, 2012, Chemotherapy research and practice.

Breast cancer and paraneoplastic cerebellar degeneration

R. Cody, D. Waterhouse, R. Natale, 1991, Cancer.

ZD1839 (Iressa): what's in it for the patient?

R. Natale, S. Zaretsky, 2002, The oncologist.

Raloxifene, an oestrogen‐receptor‐β‐targeted therapy, inhibits androgen‐independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial

M. Gross, D. Agus, Anjali Jain, 2006, BJU international.

Gemcitabine and nonplatinum combinations in non-small-cell lung cancer.

R. Natale, 2001, Oncology.

Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer.

D. Gandara, P. Lara, R. Natale, 2006, Clinical lung cancer.

A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.

H. Wakelee, R. Osarogiagbon, J. Latz, 2012, Lung cancer.

Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.

Michael Thomas, S. Thongprasert, P. Sunpaweravong, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes.

M. Aristides, G. Scagliotti, C. Gridelli, 2005, Lung cancer.

Phase II trial of AMSA in prostatic cancer.

R. Natale, R. Watson, A. Yagofa, 1982, Cancer treatment reports.

Compassionate use experience with gefitinib in poor performance (PS) patients with advanced non-small-cell lung cancer (NSCLC) treated in an expanded access program (EAP).

R. Govindan, A. Wozniak, T. Hensing, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer

R. Natale, M. Moore, J. Maroun, 1993, Investigational New Drugs.

Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Non–Small-Cell Lung Cancer: A Randomized Open-Label Phase II Study

G. Bepler, R. Ramlau, D. Talbot, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II trial of N-methylformamide in advanced head and neck cancer

R. Natale, A. Forastiere, B. Takasugi, 2004, Investigational New Drugs.

Phase II evaluation of piroxantrone in renal cell carcinoma

Mellar P. Davis, E. Crawford, R. Natale, 1992, Investigational new drugs.

An in vivo and in vitro trial of aclarubicin in metastatic breast cancer: a novel approach to the study of analogs

R. Cody, M. Simon, R. Wheeler, 2004, Cancer Chemotherapy and Pharmacology.

Single dose and steady-state pharmacokinetics of adinazolam after oral administration to man.

J. Wagner, M. Rogge, R. Natale, 1987, Biopharmaceutics & drug disposition.

Southwest Oncology Group Study 8710: trial of cystectomy alone versus neo-adjuvant M-VAC and cystectomy in patients with locally advanced bladder cancer (Intergroup Trial 0080).

E. Crawford, R. Natale, H. Burton, 1990, Progress in clinical and biological research.

Autocrine growth factors as therapeutic targets in lung cancer.

J. Mulshine, I. Avis, Y. Nakanishi, 1989, Chest.

Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer.

R. Natale, 1996, Seminars in oncology.

Bortezomib ± docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): A phase 2 study

R. Govindan, D. Carbone, F. Fossella, 2005 .

Biologically targeted treatment of non-small-cell lung cancer: focus on epidermal growth factor receptor.

R. Natale, 2003, Clinical lung cancer.

Phase II trial to topotecan in hepatocellular carcinoma: A Southwest Oncology Group study

M. O'Rourke, R. Natale, J. Macdonald, 2004, Investigational New Drugs.

O-239 Gemcitabine in the treatment of non-small cell lung cancer (NSCLC): A meta-analysis of survival and progression free survival data

G. Scagliotti, J. Vansteenkiste, J. Schiller, 2003 .

Clinical experience with Tc-99m labeled (N2S2) anti-melanoma antibody fragments and single photon emission computed tomography.

R. Wahl, N. Swanson, N. Petry, 1992, American journal of physiologic imaging.

Combination cisplatin and dichloromethotrexate in patients with advanced bladder cancer. Phase 2. A Southwest Oncology Group study.

J. Montie, E. Crawford, B. Blumenstein, 1992, The Journal of urology.

Phase II study of 5‐fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer. A southwest oncology group study

T. Fleming, C. Tangen, L. Hutchins, 1995, Cancer.

Clinical benefit with compassionate use gefitinib in a subset of non-small-cell lung cancer (NSCLC) patients with the bronchoalveolar (BAC) subtype treated during an expanded access program (EAP).

R. Govindan, A. Wozniak, T. Hensing, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Southwest Oncology Group phase H study (8504)

P. Goodman, E. Crawford, R. Natale, 1990 .

Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma

V. Sondak, E. Kraut, M. Slavik, 2004, Investigational New Drugs.

P1.01-83 IMpower150: Impact of Chemotherapy Cycles in 1L Metastatic NSCLC in Patients Treated With Atezolizumab + Bevacizumab

V. Velcheti, J. Mazières, J. Goldschmidt, 2018, Journal of Thoracic Oncology.

Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy.

J. Ahn, M. Ahn, Dong-Wan Kim, 2017 .

Irinotecan, cisplatin/carboplatin, and COX-2 inhibition in small-cell lung cancer.

R. Natale, Ronald B Natale, 2003, Oncology.

Phase (ph) 2 study of bortezomib ± docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC): Preliminary results.

K. Kelly, F. Fossella, J. Schiller, 2004, Journal of Clinical Oncology.

Multicenter phase II trial of brequinar sodium in patients with advanced melanoma.

R. Wheeler, R. Natale, M. Moore, 1992, Annals of Oncology.

Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases.

J. Ahn, M. Ahn, Dong-Wan Kim, 2017 .

Combination cyclophosphamide, Adriamycin, and vincristine rapidly alternating with combination cisplatin and VP-16 in treatment of small cell lung cancer.

R. Wittes, B. Shank, B. Shank, 1985, American Journal of Medicine.

Chemotherapy in Small Cell Lung Cancer: The Current State of the Art.

R. Natale, Natale, 1995, Seminars in radiation oncology.

In vitro comparison of the cytotoxic and cytokinetic effects of adriamycin (ADR) aclacinomycin (ACL) and carminomycin (CAR)

D. Clauw, R. Wheeler, R. Natale, 1982 .

A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status.

P. Jänne, L. Sequist, S. Gettinger, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer.

J. Hainsworth, J. Hamm, K. Albain, 2011, Lung cancer.

Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment

Edward S. Kim, C. Obasaju, M. Socinski, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor.

M. Erlander, M. Socinski, J. Neal, 2018, JCO precision oncology.

9005 Vandetanib versus erlotinib in patients with previously treated advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

S. Thongprasert, P. Sunpaweravong, D. Ferry, 2009 .

1330TiPA PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER TRIAL OF DENOSUMAB IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER.

G. Weiss, D. Spigel, J. Crawford, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I evaluation of semustine in a weekly schedule.

D. Schwalm, R. Wheeler, R. Natale, 1983, Cancer treatment reports.

Gemcitabine-containing regimens vs others in first-line treatment of NSCLC.

R. Natale, 2004, Oncology.

Patient-reported outcomes (PROs) with first-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic NSCLC: Results from MYSTIC.

N. Reinmuth, M. Ahn, F. Shepherd, 2019, Journal of Clinical Oncology.

Phase II trial of N-methylformamide in lung cancer

R. Cody, R. Natale, Jerome E. Seid, 1992, Investigational New Drugs.